TSE:MDNA

Medicenna Therapeutics Q1 2026 Earnings Results & Report

Medicenna Therapeutics logo
C$0.22 +0.04 (+22.22%)
As of 03:32 PM Eastern

Medicenna Therapeutics reported Q1 2026 earnings on April 30, 2026. The company reported EPS of -C$0.06.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens

Medicenna Therapeutics EPS Results

Actual EPS
-C$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Medicenna Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Medicenna Therapeutics Q1 2026 Earnings FAQ

Medicenna Therapeutics (TSE:MDNA) reported earnings of -C$0.06 per share for Q1 2026. The report was announced on Thursday, April 30, 2026.

Medicenna Therapeutics Earnings Headlines

Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
Medicenna Therapeutics Corp MDNA
See More Medicenna Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicenna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicenna Therapeutics and other key companies, straight to your email.

About Medicenna Therapeutics

Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company's most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe. Medicenna is also advancing MDNA11, a long-acting IL-2 Superkine designed to selectively activate cancer-fighting immune cells, which is currently being evaluated in the Phase 1/2 ABILITY-1 study and the Phase 1b NEO-CYT study. The Company is also developing MDNA113, a targeted PD-1 x IL-2 bifunctional immunotherapy for solid tumors using its proprietary BiSKIT and T-MASK platforms.

View Medicenna Therapeutics Profile